Cytosorbents (CTSO) Other Operating Expenses (2010 - 2026)

Cytosorbents has reported Other Operating Expenses for 17 years, with the latest figure at -$6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 3.79% year-over-year to -$6.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 119.29% YoY), and the FY2025 full-year result was $1.7 million, up 107.35% from the prior year.
• Other Operating Expenses for Q1 2026 stood at -$6.0 million, down from $22.1 million in the prior quarter.
• The five-year high for Other Operating Expenses was $22.1 million in Q4 2025, with the low at -$6.9 million in Q1 2024.
• Historically, Other Operating Expenses has averaged -$1.3 million across 5 years, with a median of -$3.4 million in 2023.
• Annual changes were most pronounced in 2024 — Other Operating Expenses sank 1276.29% — and 2025, when it surged 680.34%.
• Cytosorbents' Other Operating Expenses stood at $758569.0 in 2022, then plunged by 548.51% to -$3.4 million in 2023, then fell by 12.07% to -$3.8 million in 2024, then surged by 680.34% to $22.1 million in 2025, then plunged by 127.07% to -$6.0 million in 2026.
• The last three Other Operating Expenses figures came in at -$6.0 million (Q1 2026), $22.1 million (Q4 2025), and -$6.0 million (Q3 2025), per Business Quant data.